AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00918307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
Study NCT00886990 — intervention group
Intervention type: DRUG
Intervention: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Description: two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
Study NCT04223466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subxiphoid surgery procedure
Description: Subxiphoid procedure for thymectomy
Study NCT04223466 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS surgery procedure
Description: VATS procedure for thymectomy
Study NCT01591330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Reference form
Description: 80-mg tablet administered orally
Study NCT01591330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-Low
Description: 80-mg tablet administered orally
Study NCT01591330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-Medium
Description: 80-mg tablet administered orally
Study NCT01591330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023 Test-High
Description: 80-mg tablet administered orally
Study NCT02403271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: BTK Inhibitor
Study NCT02403271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti PDL-1
Study NCT01508897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose administered as subcutaneous injection
Study NCT02197637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORAL VINORELBINE
Description: Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
Study NCT02520479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-CHOP
Description: Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
Study NCT02871427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelotanserin
Description: Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Study NCT02520479 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
Study NCT01476072 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: MRI scan
Description: MRI scan only, methodology study with no other intervention
Study NCT03976128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic Walking Training
Description: The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
Study NCT03313661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
Study NCT03313661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Description: gliclazide (60-120 mg)
Study NCT03239665 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led Intervention (PHARM)
Description: 60 minute didactic lecture about vaccinations.
Study NCT03239665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led Intervention (PEER)
Description: 60 minute peer led small group intervention including skits and other educational material
Study NCT05084729 — intervention group
Intervention type: DEVICE
Intervention: Imagio OA/US
Description: Imagio optoacoustic
Study NCT02520479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-CHOP
Description: Two consolidation cycles of P-CHOP are given after radiotherapy
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib at the dose of 100 mg)
Description: 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
Description: Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
Description: Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT04444050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days
Study NCT03976128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endurance training
Description: 15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
Study NCT01180777 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (A)
Description: Daily wear contact lens
Study NCT01180777 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (B)
Description: Daily wear contact lens
Study NCT01180777 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A (C)
Description: Daily wear contact lens
Study NCT03358953 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electron Cigarette
Description: Blended Tobacco flavour, 18mg/ml
Study NCT03358953 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nicotine Replacement Patch
Description: NiQuitin 21mg
Study NCT04115059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral, daily, dosing per protocol, once a day for cycle
Study NCT02022930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros
Study NCT02022930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydros-TA
Study NCT02022930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Study NCT02602951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilot MRI program
Description: Pilot MRI program
Study NCT02602951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI with 4D Flow sequence
Description: MRI with 4D Flow sequence
Study NCT02292225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145 (duvelisib)
Description: 25mg and/or 5mg oral capsule
Study NCT02292225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000mg/40mL single-use vials
Study NCT03188471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
Study NCT03188471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
Study NCT03150186 — intervention group
Intervention type: OTHER
Intervention: SHS exposure in homes
Description: The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
Study NCT03150186 — intervention group
Intervention type: OTHER
Intervention: SHS exposure in private cars
Description: The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
Study NCT03150186 — intervention group
Intervention type: OTHER
Intervention: SHS exposure in outdoor settings
Description: In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib at the dose of 300 mg)
Description: 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Description: Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT00752986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
Description: Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
Study NCT01525758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI000413
Description: 1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
Study NCT01525758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: identical number of tablets to active drug groups
Study NCT00843570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafarelin acetate, Oestradiol Valerate, Progesterone
Description: Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (RBV)
Description: ribavirin (RBV)
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon (PegIFN) alfa-2a
Description: pegylated interferon (PegIFN) alfa-2a
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA low placebo
Description: Placebo
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA high
Description: BI 201335 NA high
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA low
Description: BI 201335 NA
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335 NA high placebo
Description: placebo
Study NCT00947349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™- HepB
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
Study NCT03227497 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole Walnuts
Description: Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
Study NCT02435043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based rehabilitation
Description: ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
Study NCT02435043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard management after stroke
Description: standard management after stroke is individualised.
Study NCT02769494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine Sustained-Release Tablets
Description: Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
Study NCT02769494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin Sodium Phosphate Injection
Description: gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
Study NCT04908007 — intervention group
Intervention type: OTHER
Intervention: Qualitative analysis for professionals
Description: 3 individual interviews with the different categories of professionals most involved during the crisis in each university hospital. In the first phase, the points of improvement identified will be analyzed In the second phase, good practices and innovations will be analyzed. For these first two phases, the duration of one hour was chosen because it is difficult to mobilize the professionals for longer. Individual interviews are preferred, but group interviews are possible with no more than three people so that everyone can express himself or herself. Finally, individual interviews of 15 to 30 minutes will be conducted with some of the people interviewed previously in order to identify the costs of the dysfunctions or problems encountered during the crisis.~Questionnaires with establishments associated with the crisis management, the ARS AuRA and France Assos Santé AuRA.~Analysis of evidence documents in the university hospitals
Study NCT04908007 — intervention group
Intervention type: OTHER
Intervention: Quantitative analysis for Professionals
Description: A self-assessment of the three phases of the crisis management process (preparation, crisis management, crisis recovery) will be carried out in the participating establishments using the WHO grid with the target persons identified within the establishments.~This step will use the crisis response assessment tool developed by the WHO following the H1N1 pandemic in 2011. This grid will be adapted beforehand to the COVID-19 situation and to the local organization by the study's scientific committee. The dimensions investigated will be : Command and control, Communication, Safety and security, Triage, Surge capacity, Continuity of essential services; Human resources, Logistics and supply management, Post-disaster recovery.~The grids will be sent to the 4 university hospitals to be filled in with the target audience recommended by the WHO methodological guide.~The results of this self-assessment will be linked to and interpreted with the results of the interviews in phase 1.
Study NCT04908007 — intervention group
Intervention type: OTHER
Intervention: Quantitative analysis for Patients
Description: A questionnaire of patients' perceptions on the same perimeter (crisis and post-crisis management, from the point of view of points of improvement and good practices) will be constructed and sent by the management of the establishments to all patients hospitalized for 48 hours or more during the first wave and who have left their email address (methods similar to the e-satis survey). The online questionnaire survey is preferred in order to get away from the emotion and for feasibility reasons. This patient experience questionnaire adapted to COVID will be co-constructed with expert/partner patients and user associations.~Four dimensions will be investigated : The perception of the quality of the information received by the patient, The nature of the information on the specific health protection protocol from which the patient benefited, The patient's consideration of the overall context, during and after, The effects of the health context on the overall management of the patient
Study NCT04908007 — intervention group
Intervention type: OTHER
Intervention: Tools development
Description: Development of tools to prepare for situations of uncertainty : In the third phase of the project, design thinking workshops will be organized (within the HCL) to develop training (in the form of simulation) in order to appropriate virtuous practices in situations of uncertainty. The purpose of these training sessions will be to improve the institution's ability to learn in a situation of uncertainty and thus to develop its reliability.~The aim of these workshops is to provide tools for raising awareness of situations of uncertainty to all hospital staff.
Study NCT03161158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHIARA-System
Description: Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
Study NCT03161158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care IV diuretics
Description: Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
Study NCT03989648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esmarch bandages
Description: Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
Study NCT03989648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simple leg elevation
Description: simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
Study NCT03883412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks of treatment
Study NCT03883412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 16 weeks of Liraglutide
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ ACWY
Description: One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
Study NCT00291343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months